Terms: = Kidney tumors AND BCL3, P20749, 602, ENSG00000069399, D19S37, BCL4 AND Clinical Outcome
3 results:
1. Predictors of adverse prognosis in COVID-19: A systematic review and meta-analysis.
Figliozzi S; Masci PG; Ahmadi N; Tondi L; Koutli E; Aimo A; Stamatelopoulos K; Dimopoulos MA; Caforio ALP; Georgiopoulos G
Eur J Clin Invest; 2020 Oct; 50(10):e13362. PubMed ID: 32726868
[TBL] [Abstract] [Full Text] [Related]
2. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
[TBL] [Abstract] [Full Text] [Related]
3. The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients.
Al-Marrawi MY; Rini BI; Harshman LC; Bjarnason G; Wood L; Vaishampayan U; MacKenzie M; Knox JJ; Agarwal N; Al-Harbi H; Kollmannsberger C; Tan MH; Rha SY; Donskov FN; North S; Choueiri TK; Heng DY;
Target Oncol; 2013 Sep; 8(3):203-209. PubMed ID: 23300029
[TBL] [Abstract] [Full Text] [Related]
